285 related articles for article (PubMed ID: 36549855)
1. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.
Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855
[TBL] [Abstract][Full Text] [Related]
2. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
[TBL] [Abstract][Full Text] [Related]
3. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study.
Song YJ; Cho SK; Kim JY; You SH; Kim H; Jung SY; Sung YK
Semin Arthritis Rheum; 2023 Aug; 61():152214. PubMed ID: 37172496
[TBL] [Abstract][Full Text] [Related]
4. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
[TBL] [Abstract][Full Text] [Related]
5. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
[TBL] [Abstract][Full Text] [Related]
6. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
[TBL] [Abstract][Full Text] [Related]
8. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.
Tsai JJ; Liu LT; Chen CH; Chen LJ; Wang SI; Wei JC
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37479495
[TBL] [Abstract][Full Text] [Related]
10. Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry.
Mok CC; So H; Yim CW; To CH; Lao WN; Wong SPY; Ng HY; Lee JMY; Lee PML; Ying SKY; Leung MH; Ho CTK
Rheumatology (Oxford); 2024 Feb; 63(2):358-365. PubMed ID: 37129549
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.
Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Burden AM; Dreyer L
Rheumatology (Oxford); 2024 Jan; 63(1):93-102. PubMed ID: 37052534
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Russell MD; Stovin C; Alveyn E; Adeyemi O; Chan CKD; Patel V; Adas MA; Atzeni F; Ng KKH; Rutherford AI; Norton S; Cope AP; Galloway JB
Ann Rheum Dis; 2023 Aug; 82(8):1059-1067. PubMed ID: 37247942
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
Lauper K; Iudici M; Mongin D; Bergstra SA; Choquette D; Codreanu C; Cordtz R; De Cock D; Dreyer L; Elkayam O; Hauge EM; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Kristianslund EK; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Strangfeld A; Verschueren P; Courvoisier DS; Finckh A
Ann Rheum Dis; 2022 Oct; 81(10):1358-1366. PubMed ID: 35705376
[TBL] [Abstract][Full Text] [Related]
14. Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs.
Singh N; Gold LS; Lee J; Wysham KD; Andrews JS; Makris UE; England BR; George MD; Baker JF; Jarvik J; Heagerty PJ; Singh S
Arthritis Care Res (Hoboken); 2024 May; 76(5):627-635. PubMed ID: 38116680
[TBL] [Abstract][Full Text] [Related]
15. Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis.
Chen YW; Chen HH; Huang WN; Chen JP; Chen YH; Chen YM
Clin Rheumatol; 2024 Jan; 43(1):117-128. PubMed ID: 37658935
[TBL] [Abstract][Full Text] [Related]
16. Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data.
Jung SM; Kwok SK; Ju JH; Park YB; Park SH
Korean J Intern Med; 2019 May; 34(3):669-677. PubMed ID: 29172405
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study.
Song YJ; Cho SK; Kim H; Kim HW; Nam E; Jeon JY; Yoo HJ; Choi CB; Kim TH; Jun JB; Bae SC; Yoo DH; Sung YK
Sci Rep; 2023 May; 13(1):7877. PubMed ID: 37188765
[TBL] [Abstract][Full Text] [Related]
18. Continuity of Care Within a Single Patient Support Program for Patients with Rheumatoid Arthritis Prescribed Second or Later Line Advanced Therapy.
Fendrick AM; Mease P; Davis M; Patel P; Matthias W; Nunag D; Mittal M
Adv Ther; 2023 Mar; 40(3):990-1004. PubMed ID: 36604404
[TBL] [Abstract][Full Text] [Related]
19. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Etani Y; Maeda Y; Okita Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Hara R; Nagai K; Hiramatsu Y; Son Y; Amuro H; Fujii T; Okano T; Ueda Y; Katayama M; Okano T; Tachibana S; Hayashi S; Kumanogoh A; Okada S; Nakata K
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597846
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
